Elkfork Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Elkfork Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$20.2M	Buy	119,308 +36,596	+44%	+$6.47M	0.49%	50
2019 Q2	$15.2M	Sell	82,712 -7,252	-8%	-$1.27M	0.37%	62
2019 Q1	$16.5M	Buy	89,964 +1,708	+2%	+$315K	0.42%	60
2018 Q4	$14.6M	Sell	88,256 -3,696	-4%	-$640K	0.41%	56
2018 Q3	$17.7M	Sell	91,952 -5,572	-6%	-$992K	0.42%	60
2018 Q2	$16.6M	Sell	97,524 -868	-0.9%	-$135K	0.43%	58
2018 Q1	$16M	Buy	98,392 +44,940	+84%	+$7.34M	0.43%	56
2017 Q4	$8.01M	Sell	53,452 -1,484	-3%	-$220K	0.22%	96
2017 Q3	$8.35M	Sell	54,936 -19,236	-26%	-$2.9M	0.24%	84
2017 Q2	$9.56M	Sell	74,172 -3,080	-4%	-$371K	0.29%	71
2017 Q1	$8.45M	Sell	77,252 -7,644	-9%	-$673K	0.26%	75
2016 Q4	$6.25M	Buy	+84,896	New	+$6.91M	0.21%	90

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Elkfork Partners's VRTX Position: Q3 2019 in Review

Elkfork Partners increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q3 2019, buying an estimated $6.47M and bringing the position to 119,308 shares worth $20.2M. The position accounts for 0.49% of the portfolio, ranked #50.

Elkfork Partners first reported a position in VRTX in Q4 2016 and has held it in 12 quarters since. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Elkfork Partners held 119,308 shares of Vertex Pharmaceuticals worth $20.2M as of Q3 2019.
Elkfork Partners bought 36,596 Vertex Pharmaceuticals shares in Q3 2019, an estimated $6.47M.
Vertex Pharmaceuticals made up 0.49% of Elkfork Partners's portfolio in Q3 2019, its #50 holding.
Elkfork Partners first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.